CONICET Posdoctoral fellow
Director: José Luis Barra
Production of recombinant proteins for therapeutic use with high socio-economic impact
The aim of our project is to develop, and subsequently transfer to the productive sector, the biotechnological processes for the production of therapeutic recombinant proteins with high socio-economic impact. One of them is human DNase I used for the treatment of cystic fibrosis, one of the most common lethal inherited genetic diseases (autosomal recessive) in Caucasian population with an incidence of approximately 1/2500 births. Human beta-glucocerebrosidase is other of the recombinant proteins of interest. This therapeutic enzyme is successfully used in the treatment of Gaucher’s disease, a rare genetic disorder (autosomal recessive) whose treatment is amongst the most expensive on a cost-per-patient basis.